According to the latest data from the Hong Kong Stock Exchange, a significant position change occurred for HAIXI PHARMA (02637) on July 9th. The total value of securities deposited reached 2.013 billion Hong Kong dollars, representing 12.60% of its holdings.

A major shareholder of the company deposited 9.8733 million shares with CMB International Securities, resulting in an increase in the shareholder's holding proportion by 12.55%.

In a separate announcement, the company stated that its self-developed C019199 tablets have formally initiated a Phase III clinical trial (CTR20261818) for osteosarcoma patients who have failed at least two prior lines of treatment. The relevant information has been published on the drug clinical trial registration and information disclosure platform of the Center for Drug Evaluation (CDE) under China's National Medical Products Administration (NMPA).